<DOC>
	<DOCNO>NCT01182194</DOCNO>
	<brief_summary>This study design compare relative bioavailability ( rate extent absorption ) 3 mg/0.02 mg Drospirenone/Ethinyl Estradiol Tablets YAZÂ® Tablets ( Berlex , Inc. ) follow single , oral dose ( 2 x 3 mg/0.02 mg tablet ) healthy , adult subject administer fasting condition .</brief_summary>
	<brief_title>Drospirenone/Ethinyl Estradiol ( 3 mg/0.02 mg ) Tablets Under Fasting Conditions .</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA Bioequivalence Statistical Methods</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<criteria>Subjects inform nature study agree read , review , sign inform consent document prior Period I dose . Subjects complete screen process within 28 day prior Period I dose . Subjects healthy adult menstruate woman 18 35 year age , inclusive , time dose . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive , weigh least 110 pound . Subjects healthy document medical history , physical examination , vital sign assessment , general observation . The physical examination also include gynecological exam . If subject complete acceptable Pap smear gynecological exam previous 12 month ( prior study Day 1 ) documentation acceptable result provide , deferred . Any abnormalities/deviations normal range consider clinically relevant study physician investigator evaluate individual case , document study file , agree upon study physician investigator prior enrol volunteer study continue enrollment . Female subject practice acceptable nonhormonal method birth control judge investigator ( ) least 14 day prior Period I dose throughout study 14 day Period II dosing . The acceptable nonhormonal birth control method include : double barrier , nonhormonal releasing intrauterine device place least 30 day prior dose , abstinence throughout duration study , surgically sterile least 6 month prior Period I dose . Volunteers report receive investigational drug within 30 day prior Period I dose . Volunteers report take oral contraceptive include estrogen progestin combine pill progestin pill patch within 28 day prior Period I dose , use injectable contraceptive within 6 month Period I dose . Volunteers ever progestational hormone implant . Volunteers report presence history clinically significant disorder involve cardiovascular , respiratory , renal , liver , gastrointestinal , immunologic , hematologic , endocrine , neurologic system ( ) psychiatric epilepsy disease determine clinical investigator ( ) . Volunteers report presence history migraine severe headache . Volunteers systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 45 90 mmHg exclude study . Volunteers history thrombotic disorder ever cerebrovascular accident transient ischemic attack . Volunteer history breast cancer undiagnosed breast nodule , active malignancy , undiagnosed vaginal bleeding . Volunteers condition may aggravate fluid retention determine principal investigator . Volunteers history jaundice previous use oral contraceptive kinds hormonal contraceptive . Volunteers whose clinical laboratory test value outside accept reference range confirm reexamination deem clinically significant . Volunteers demonstrate reactive screen hepatitis B surface antigen , hepatitis C antibody , HIV antibody . Volunteers report history allergic response ( ) drospirenone/ethinyl estradiol , progestin/estrogens , relate drug . Volunteers report use systemic prescription medication 14 day prior Period I dose ( exception hormonal contraceptive ) . Volunteers report use drug know induce inhibit hepatic drug metabolism 28 day prior Period I dose . Volunteers report history clinically significant allergy include drug allergy . Volunteers report clinically significant illness 4 week prior Period I dose ( determined clinical investigator ) . Volunteers report history drug alcohol addiction abuse within past year . Volunteers demonstrate positive drug abuse screen study prior Period I dose . Volunteers use tobacco product past 6 month . Volunteers report donate great 150 mL blood within 30 day prior Period I dose . All subject advise donate blood 4 week complete study . Volunteers report donate plasma within 30 day prior Period I dose . All subject advise donate plasma 4 week complete study . Volunteers demonstrate positive pregnancy screen . Volunteers currently breastfeed . Volunteers use within 3 month precede Period I dose vaginally administer estrogen progestin containing product . Any volunteer engage unprotected sexual intercourse time interval start 14 day prior first period 14 day Period II dosing . Volunteers hysterectomy oophorectomy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>